

Literaturverzeichnis

zum Titelthema „S3-Leitlinie Prostatakarzinom“, von Professor Dr. Maximilian Burger, Bayerisches Ärzteblatt 6/2017, Seite 264 ff.

1. Robert Koch-Institut (RKI), Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID). Krebs in Deutschland 2003-2004. Häufigkeiten und Trends. 6th ed. Berlin: RKI; 2008.
2. Nelson WG. Prostate cancer prevention. *Curr Opin Urol* 2007;17(3):157-67
<http://www.ncbi.nlm.nih.gov/pubmed/17414513>.
3. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. *JAMA* 2006;296(19):2351-61
4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr. The influence of finasteride on the development of prostate cancer. *The New England journal of medicine* 2003;349(3):215-24
5. Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Levesque J, Brousseau G, Belanger A, Labrie F. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. *Prostate* 2000;45(1):19-35
6. Bill-Axelsson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy versus watchful waiting in early prostate cancer. *The New England journal of medicine* 2011;364(18):1708-17
7. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. *Cochrane Database Syst Rev* 2013;1:CD004720
8. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. *Cancer* 2011;117(6):1210-9
9. Valerio M, Donaldson I, Emberton M, Ehdai B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *Eur Urol* 2015;68(1):8-19
10. Shakespeare TP. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. *Radiat Oncol* 2015;10:233

11. Reese AC, Landis P, Han M, Epstein JI, Carter HB. Expanded Criteria to Identify Men Eligible for Active Surveillance of Low-Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis. *Journal of Urology* 2013
12. Asimakopoulos AD, Pereira Fraga CT, Annino F, Pasqualetti P, Calado AA, Mugnier C. Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. *J Sex Med* 2011;8(5):1503-12
13. Hollenbeck BK, Dunn RL, Miller DC, Daignault S, Taub DA, Wei JT. Volume-based referral for cancer surgery: informing the debate. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007;25(1):91-6
14. Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, Hirano D, Takimoto Y, Kamoto T, Ogawa O, Sumiyoshi Y, Shimazaki J, Kakizoe T. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. *Jpn J Clin Oncol* 2006;36(12):789-93
15. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 2009;181(3):956-62
16. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol* 2016;17(8):1061-9
17. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. *The New England journal of medicine* 2011;364(21):1995-2005
18. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de WR, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367(13):1187-97
19. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *The New England journal of medicine* 2015;373(8):737-46